Pfizer Inc. cash flow to debt ratio of 17.36% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Pfizer Inc.'s free cash flow has decreased 7.72% from $9.84B last year to $9.08B, signaling decreasing performance

Pfizer Inc.'s debt to equity ratio is 0.74, which means that the company's assets are unhealthy financed, signaling financial risk.

Pfizer Inc.'s debt has decreased relative to shareholder equity from 0.76 last year to 0.74 today, signaling strengthened financials

Pfizer Inc. has a net debt to EBITDA ratio of 3.57x, which exceeds the 3.00x threshold, indicating high leverage and potential financial risk

Pfizer Inc.'s interest coverage ratio of 5.92 indicates that earnings with good margin can cover interest payments on company debt

Pfizer Inc.'s profit margin has decreased (46.01%) in the last year from 12.60% to 6.81%, signaling decreasing performance

Pfizer Inc.'s short-term assets of $42.90B exceed its short-term liabilities of $36.98B

Pfizer Inc.'s return on assets of 2.16% is lower than the 5.00% threshold, indicating inefficient asset utilization

Pfizer Inc.'s return on equity of 4.89%, is lower than 15.00%, indicating bad performance

Pfizer Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

Pfizer Inc. had positive net income in 5 out of 5 years, indicating stable and consistent earnings

Pfizer Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Pfizer Inc. has a free cash flow yield of 5.89%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Pfizer Inc.'s yearly earnings has decreased 3.12% since last year from $8.02B to $7.77B, signaling decreasing performance

Pfizer Inc.'s yearly revenue has decreased 1.65% since last year from $63.63B to $62.58B, signaling decreasing performance

ROIC 9.33% (Source: FMP key-metrics). In the 5–10% partial-credit band. Score: 1 of 2. This band sits within the typical US weighted-average cost of capital range. Methodology choice can change the conclusion: under FMP's invested-capital definition the company is at or near its cost of capital; under narrower operating-capital definitions the same company may score higher. Invested capital here includes equity, non-current liabilities, and short-term debt. Cash is not subtracted. See methodology.

Pfizer Inc.'s 3-year revenue CAGR of -14.56% is negative, indicating declining revenue over the past 3 years

Pfizer Inc. had revenue growth in 3 out of 5 years, indicating consistent revenue performance

Pfizer Inc. had positive ROE in 5 out of 5 years, indicating consistent and reliable returns on equity

Pfizer Inc. is overvalued relative to its fair value price of 3.51 based on Discounted Cash Flow model

Pfizer Inc. has an earnings yield of 2.81%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings

Pfizer Inc. is overvalued relative to its fair value price of 6.93 based on EBITDA multiple model

Pfizer Inc. has an EV/EBITDA ratio of 13.78x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

Pfizer Inc. is undervalued relative to its fair value price of 69.09 based on Earnings Fair Value model

Pfizer Inc.'s earnings growth over the measurement period is negative; the PEG ratio is not meaningful and the check fails.

Pfizer Inc. has a price-to-book ratio of 1.80x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Pfizer Inc. has a price-to-sales ratio of 2.42x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue